Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - diovan ® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progr

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

physicians total care, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 80 mg - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with diovan hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national comm

Belgia - olandeză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - valsartan 80 mg - filmomhulde tablet - 80 mg - valsartan 80 mg - valsartan

Portugalia - portugheză - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - valsartan + hidroclorotiazida - comprimido revestido por película - 80 mg + 12.5 mg - valsartan 80 mg ; hidroclorotiazida 12.5 mg - valsartan and diuretics - genérico - duração do tratamento: longa duração

Canada - franceză - Health Canada

novartis pharmaceuticals canada inc - valsartan - comprimé - 80mg - valsartan 80mg - angiotensin ii receptor antagonists

Belgia - franceză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - valsartan 80 mg - comprimé pelliculé - 80 mg - valsartan 80 mg - valsartan

Taiwan - chineză - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

台灣諾華股份有限公司 台北市中山區民生東路三段2號8樓 (01516589) - valsartan - 膜衣錠 - valsartan (2408005100) mg - valsartan - 治療成人和6-18 歲的兒童或青少年高血壓、心衰竭(nyha 二到四級)、心肌梗塞後左心室功能異常。

Taiwan - chineză - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

台灣諾華股份有限公司 台北市中山區民生東路三段2號8樓 (01516589) - valsartan - 膜衣錠 - 主成分 () ; valsartan (2408005100) mg - valsartan - 治療成人和6-18 歲的兒童或青少年高血壓、心衰竭(nyha 二到四級)、心肌梗塞後左心室功能異常。

Canada - engleză - Health Canada

novartis pharmaceuticals canada inc - valsartan - tablet - 80mg - valsartan 80mg - angiotensin ii receptor antagonists

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

stat rx usa llc - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - hydrochlorothiazide 12.5 mg - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension. diovan hct may be used in patients whose blood pressure is not adequately controlled on monotherapy. diovan hct may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. the choice of diovan hct as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. individual blood pressure goals may vary based upon the patient’s risk. d